High p16 Expression Is Associated with Malignancy and Shorter Disease-Free Survival Time in Solitary Fibrous Tumor/Hemangiopericytoma

Abstract

Objective Solitary fibrous tumors (SFT) and hemangiopericytomas (HPC) are now classified along a single spectrum of fibroblastic mesenchymal tumors with NAB2–STAT6 fusion. This fusion acts as a driver mutation that constitutively activates EGR1, which is known to be involved in the p16 pathway. Overexpression of p16 is associated with malignancy and worse prognosis in multiple mesenchymal tumors. The authors sought to investigate p16 immunoexpression in association with malignancy and prognosis of SFT/HPC tumors.

Design Twenty-three SFT/HPC tumors (central nervous system [CNS]: 12, non CNS: 11) diagnosed at our institution from 2002 to 2016 were assigned into 3 grades. Data from microarray immunohistochemistry for STAT6, synaptophysin, CD56, chromogranin, SST2A, EGR1, Ki67, and p16, grade and survival were analyzed.

Results CNS SFT/HPCs tend to be malignant (grade 3; 67 vs. 18%, p = 0.036) and more likely to express synaptophysin (33 vs. 0%, p = 0.035) than non CNS tumors. Overexpression of p16 (immunopositivity ≥ 50% tumor cells) was associated with malignant (grade 3) tumors, and has a sensitivity of 70% (7/10), and a specificity of 77% (10/13), as a predictive marker for malignancy. SFT/HPC patients with low p16 expression demonstrated significantly longer disease-free survival time (median survival > 113 months) than those with high p16 expression (median survival = 30 months, p = 0.045).

Conclusions SFT/HPCs in the CNS are more likely to be malignant than the tumors in other sites. High p16 expression is also associated with malignancy and shorter disease-free survival time in SFT/HPC tumors in our study cohort. Clinically, p16 overexpression can be used as predictive marker for malignancy and prognosis and a possible therapeutic target.

Keywords

solitary fibrous tumor - hemangiopericytoma - p16 - malignancy - disease-free survival time

Authors' Contributions

Study design: Y.L., R.S.H., J.K.W., C.B.H., A.S.T., and K.A.

Study conduct and data analysis: Y.L., K.A., and R.S.H.

Manuscript preparation: Y.L., K.A., and R.S.H.

• References

• 1 Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 2014; 27 (03) 390-395
• 2 Robinson DR, Wu YM, Kalyana-Sundaram S. , et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 2013; 45 (02) 180-185
• 3 Chmielecki J, Crago AM, Rosenberg M. , et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 2013; 45 (02) 131-132
• 4 Zwang Y, Oren M, Yarden Y. Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Res 2012; 72 (05) 1051-1054
• 5 Virolle T, Adamson ED, Baron V. , et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001; 3 (12) 1124-1128
• 6 Chaturvedi V, Cesnjaj M, Bacon P. , et al. Role of INK4a/Arf locus-encoded senescent checkpoints activated in normal and psoriatic keratinocytes. Am J Pathol 2003; 162 (01) 161-170
• 7 Honoki K, Stojanovski E, McEvoy M. , et al. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. Cancer 2007; 110 (06) 1351-1360
• 8 Kammerer-Jacquet SF, Thierry S, Cabillic F. , et al. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. Hum Pathol 2017; 59: 34-40
• 9 Gannon BR, Manduch M, Childs TJ. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Int J Gynecol Pathol 2008; 27 (01) 68-73
• 10 Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. IARC/WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. WHO; 2013: 80-82
• 11 Louis DN, Perry A, Reifenberger G. , et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131 (06) 803-820
• 12 Schweizer L, Koelsche C, Sahm F. , et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013; 125 (05) 651-658
• 13 Berghoff AS, Kresl P, Bienkowski M. , et al. Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma. Clin Neuropathol 2017; 36 (02) 56-59
• 14 Vogels RJ, Vlenterie M, Versleijen-Jonkers YM. , et al. Solitary fibrous tumor - clinicopathologic, immunohistochemical and molecular analysis of 28 cases. Diagn Pathol 2014; 9: 224
• 15 Cai YH, Huang H. Advances in the study of protein-DNA interaction. Amino Acids 2012; 43 (03) 1141-1146
• 16 Romagosa C, Simonetti S, López-Vicente L. , et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30 (18) 2087-2097
• 17 Martin A, Baran-Marzak F, El Mansouri S. , et al. Expression of p16/INK4a in posttransplantation lymphoproliferative disorders. Am J Pathol 2000; 156 (05) 1573-1579
• 18 Reuschenbach M, Waterboer T, Wallin KL. , et al. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 2008; 123 (11) 2626-2631
• 19 Knösel T, Altendorf-Hofmann A, Lindner L. , et al. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier. J Clin Pathol 2014; 67 (07) 592-598
• 20 Shim BY, Yoo J, Lee YS, Hong YS, Kim HK, Kang JH. Prognostic role of Rb, p16, Cyclin D1 proteins in soft tissue sarcomas. Cancer Res Treat 2010; 42 (03) 144-150
• 21 Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer. EBioMedicine 2016; 8: 30-39